Down-regulation of orexin gene expression by severe obesity in the rats: Studies in Zucker fatty and Zucker diabetic fatty rats and effects of rosiglitazone

Molecular Brain Research

Volumn 77, Issue 1, 2000, Pages 131-137

  Cai, Xue J ^a   Lister, Carolyn A ^b   Buckingham, Robin E ^b   Pickavance, Lucy ^a   Wilding, John ^a   Arch, Jonathan R S ^b   Wilson, Shelagh ^b   Williams, Gareth ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Obesity; Orexins hypocretins; Thiazolidinedione; Zucker diabetic fatty rats; Zucker fatty rats

Indexed keywords

CHOLESTEROL; FATTY ACID; GLUCOSE; INSULIN; LEPTIN; OREXIN; ROSIGLITAZONE; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFICACY; FATTY ACID BLOOD LEVEL; FOOD INTAKE; GENE EXPRESSION REGULATION; GLUCOSE HOMEOSTASIS; INSULIN BLOOD LEVEL; MALE; NEUROENDOCRINOLOGY; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; RAT; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 2; GENE EXPRESSION REGULATION; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; HYPOTHALAMUS; INSULIN; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LEPTIN; NEUROPEPTIDES; OBESITY; PROTEIN PRECURSORS; RATS; RATS, ZUCKER; RNA, MESSENGER; THIAZOLES; THIAZOLIDINEDIONES; THINNESS; TRANSCRIPTION, GENETIC;

ANIMALIA;

EID: 0034646779     PISSN: 0169328X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-328X(00)00041-3     Document Type: Article

References (41)

1. Adams M., Montague C.T., Prins J.B., Holder J.C., Smith S.A., Sanders L., Digby J.E., Sewter C.P., Lazar M.A., Chatterjee K.K., O'Rahilly S. Activators of peroxisome proliferator-activated receptor g have depot-specific effects on human preadipocyte differentiation. J. Clin. Invest. 100:1997;3149-3153.
2. Balfour J.A., Plosker G.L. Rosiglitazone. Drugs. 57:1999;921-930.
3. Buckingham R., Toseland N., Hughes C., Lister C., Smith S. The PPARγ agonist BRL 49653, prevent degenerative changes in pancreatic islet β-cell in ZDF rats. Diabetes. 46:1997;638.
4. Cai X.J., Widdowson P., Harrold J., Wilson S., Buckingham R., Arch J., Tadayyon M., Clapham J.C., Wilding J., Williams G. Hypothalamic orexin expression: modulation by blood glucose and feeding. Diabetes. 48:1999;2132-2137.
5. Chemelli R.M., Willie J.T., Sinton C.M., Elmquist J.K., Scammell T., Lee C., Richardson J.A., Williams S.C., Xiong Y., Kisanuki Y., Fitch T.E., Nakazato M., Hammer R.E., Saper C.B., Yanagisawa M. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell. 98:1999;437-451.
6. Chua S.C., Chung W.K., Wu-peng X.S., Zhang Y., Liu S.M., Tartaglia L.A., Leibel R.L. Phenotypes of mouse diabetes and rat fatty due to mutation in the ob (leptin) receptor. Science. 271:1996;994-996.
7. Cutler D.J., Morris R., Sheridhar V., Wattam T.A.K., Holmes S., Patel S., Arch J.R.S., Wilson S., Buckingham R.E., Evans M.L., Leslie R.A., Williams G. Differential distribution of orexin-A and orexin-B immunoreactivity in the rat brain and spinal cord. Peptides. 20:1999;1455-1470.
8. Date Y., Ueta Y., Yamashita H., Yamaguchi H., Matsukura S., Kangawa K., Sakurai T., Yanagisawa M., Nakazato M. Orexins, orexigenic hypothalamic peptides, interact with autonomic, neuroendocrine and neuroregulatory systems. Proc. Natl. Acad. Sci. USA. 96:1999;748-753.
9. Day C. Thiazolidinediones: a new class of antidiabetic drugs. Diabetic Medicine. 16:1999;179-192.
10. Delecea L., Kilduff T.S., Peyron C., Gao X.B., Foye P.E., Danielson P.E., Fukuhara C., Battenberg E.F., Gautvik V.T., Bartlett F.S., Frankel W.N., Vandenpol A.N., Bloom F.E., Gautvik K.M., Sutcliffe J.G. The hypocretins-hypothalamus-specific peptides with neuroexcitatory activity. Proc. Natl. Acad. Sci. USA. 95:1998;322-327.
11. Doyle P., Rohner-Jeanrenaud F., Jeanrenaud B. Local cerebral glucose utilization in brain of lean and genetically obese (fa/fa) rats. Am. J. Physiol. 264:1993;E29-E36.
12. Edwards C.B., Abusnana S., Sunter D., Murphy K.G., Ghatei M.A., Bloom S.R. The effect of the orexins on food intake: comparison with neuropeptide Y, melanin-concentrating hormone and galanin. J. Endocrinol. 160:1999;R7-R12.
13. Hakansson M., De Lecea L., Sutcliffe J.G., Yanagisawa M., Meister B. Leptin receptor-and STAT-immunoreactivities in hypocretin/orexin neurones of the lateral hypothalamus. J. Neuroendocrinol. 11:1999;653-663.
14. Horvath T.L., Diano S., van den Pol A.N. Synaptic interaction between hypocretin (orexin) and neuropeptide Y cells in the rodent and primate hypothalamus: A novel circuit implicated in metabolic and endocrine regulations. J. Neurosci. 19:1999;1072-1087.
15. Ida T., Nakahara K., Katayama T., Murakami N., Nakazato M. Effect of lateral cerebroventricular injection of the appetite-stimulating neuropeptide, orexin and neuropeptide Y, on the various behavioral activities of rats. Brain Res. 821:1999;526-529.
16. Iida M., Murakami T., Ishida K., Mizuno A., Kuwajima M., Shima K. Substitution at codon 269 (glutamine→proline) of the leptin receptor (OB-R) cDNA is the only mutation found in the Zucker fatty (fa/fa) rat. Biochem. Biophys. Res. Commun. 224:1996;597-604.
17. Jain M.R., Horvath T.L., Kalra P.S., Kalra S.P. Evidence that NPY Y1 receptors are involved in stimulation of feeding by orexins (hypocretins) in sated rats. Regulatory Peptides. 87:2000;19-24.
18. Kim E.M., Grace M.K., Welch C.C., Billington C.J., Levine A.S. STZ-induced diabetes decreases and insulin normalizes POMC mRNA in arcuate nucleus and pituitary in rats. Am. J. Physiol. 45:1999;R1320-R1326.
19. Lin L., Faraco J., Li R., Kadotani H., Roger W., Lin X., Qiu X., de Jong P.J., Nishino S., Mignot E. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell. 98:1999;365-376.
20. Maggio C.A., Pi-Sunyer F.X. The prevention and treatment of obesity-application to type 2 diabetes. Diabetes Care. 20:1997;1744-1766.
21. Mondal M.S., Nakazato M., Date Y., Murakami N., Yanagisawa M., Matsukura S. Widespread distribution of orexin in rat brain and its regulation upon fasting. Biochem. Biophys. Res. Commun. 256:1999;495-499.
22. Okuno A., Tamemoto H., Tobe K., Ueki K., Mori Y., Iwamoto K., Umesono K., Akanuma Y., Fujiwara T., Horikoshi H., Yazaki Y., Kadowaki T. Troglitazone increases the number of small adipocytes without change of white adipose tissue mass in obese Zucker rats. J. Clin. Invest. 101:1998;1354-1361.
23. Patel J., Miller E., Hu J., Granett J. BRL 49653 (a thiazolidinedione) improves glycemic control in NIDDM patients. Diabetes. 46:(suppl. 1):1997;577.
24. Peyron C., Tighe D.K., Vandenpol A.N., Delecea L., Heller H.C., Sutcliffe J.G., Kilduff T.S. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J. Neurosci. 18:1998;9996-10015.
25. Phillips M.S., Liu Q., Hammond H.A., Dugan V., Hey P.J., Caskey C.J., Hess J.F. Leptin receptor missense mutation in the fatty Zucker rat. Nature Genetics. 13:1996;18-19.
26. Pick A., Clark J., Kubstrup C., Levisetti M., Pugh W., Bonner-Weir S., Polonsky K.S. Role of apoptosis in failure of beta-cell mass compensation for insulin resistance and beta-cell defects in the male zucker diabetic fatty rat. Diabetes. 47:1998;358-364.
27. Pickavance L., Widdowson P.S., King P., Ishii S., Tanaka H., Williams G. The development of overt diabetes in young Zucker diabetic fatty (ZDF) Rats and the effects of chronic MCC-555 treatment. Br. J. Pharmacol. 125:1998;767-770.
28. Rossi M., Kim M.S., Morgan D.A., Small C.J., Edwards C.B., Sunter D., Abusnana S., Goldstone A.P., Russell S.H., Stanley S.A., Smith D.M., Yagaloff K., Ghatei M.A., Bloom S.R. A C-terminal fragment of agouti-related protein increases feeding and antagonizes the effect of alpha-melanocyte stimulating hormone in vivo. Endocrinology. 139:1998;4428-4431.
29. Rouch C., Nicolaidis S., Orosco M. Determination, using microdialysis, of hypothalamic serotonin variations in response to different macronutrients. Physiol. Behav. 65:1999;653-657.
30. Sakurai T., Amemiya A., Ishii M., Matsuzaki I., Chemelli R.M., Tanaka H., Williams S.C., Richardson J.A., Kozlowski G.P., Wilson S., Arch J.S., Buckingham R.E., Haynes A.C., Carr S.A., Annan R.S., Mcnulty D.E., Liu W.S., Terrett J.A., Elshourbagy N.A., Bergsma D.J., Yanagisawa M. Orexins and orexin receptors - a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell. 92:1998;573-585.
31. Schwartz M.W., Seeley R.J., Woods S.C., Weigle D.S., Campfield L.A., Burn P., Baskin D.G. Leptin increased hypothalamic pro-opiamelanocortin mRNA expression in the rostral arcuate nucleus. Diabetes. 46:1997;2119-2123.
32. Sweet D.C., Levine A.S., Billington C.J., Kotz C.M. Feeding response to central orexins. Brain Res. 821:1999;535-538.
33. Taheri S., Mahmoodi M., Opacka-Juffry J., Ghatei M., Bloom S.R. Distribution and quantification of immunoreactive orexin A in rat tissues. FEBS Lett. 457:1999;157-161.
34. Upton R., Widdowson P.S., Ishii S., Tanaka H., Williams G. Improved metabolic status and insulin sensitivity in obese fatty (fa/fa) Zucker rats and Zucker Diabetic Fatty (ZDF) rats treated with the thiazolidinedione, MCC-555. Br. J. Pharmacol. 125:1998;1708-1714.
35. Uysal K.T., Wiesbrock S.M., Marino M.W., Hotamisligil G.S. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature. 389:1997;610-614.
36. Wang Q., Dryden S., Frankish H.M., Bing C., Pickavance L., Hopkins D., Buckingham R., Williams G. Increased feeding in fatty Zucker rats by the thiazolidinedione BRL 49653 (rosiglitazone) and the possible involvement of leptin and hypothalamic neuropeptide Y. Br. J. Pharmacol. 122:1997;1405-1410.
37. Werner J., Bienek A. The significance of nucleus raphe dorsalis and centralis for thermoafferent signal transmission to the preoptic area of the rat. Exp. Brain Res. 59:1985;543-547.
38. White B.D., Martin R.J. Evidence for a central mechanism of obesity in the Zucker rat: role of neuropeptide Y and leptin. Proc. Soc. Exp. Biol. Med. 214:1999;222-232.
39. Williams G., Steel J.H., Cardoso H., Ghatei M.A., Lee Y.C., Gill J.S., Burrin J.M., Polak J.M., Bloom S.R. Increased hypothalamic neuropeptide Y in the streptozotocin-diabetic rats. Diabetes. 37:1988;763-772.
40. Yamamoto Y., Ueta Y., Date Y., Nakazato M., Hara Y., Serino R., Nomura M., Sibuya I., Matsukura S., Yamashita H. Down regulation of the prepro-orexin gene expression in genetically obese mice. Mol. Brain Res. 65:1999;14-22.
41. Zhang Y., Proenca M., Maffei M., Barone M., Leopold L., Friedman J.M. Positional cloning of the mouse obese gene and its human homologue. Nature. 372:1994;425-432.